Skip to content

Study · Not a test of the peptide alone · 1998

2 results

Binding sites for growth hormone-releasing peptide.

Ong H, Bodart V, McNicoll N, Lamontagne D, Bouchard JF

Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society1 Apr 1998Cited by 17 (Europe PMC)

PMID10990149 (opens in a new tab)DOI10.1016/s1096-6374(98)80038-5 (opens in a new tab)PepBankPUB-10990149
Source linkPubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Hexarelin.

  1. 01LabNot a test of Hexarelin aloneEx vivo tissueMechanism

    In human, bovine and porcine anterior pituitary membranes, a hexarelin derivative labelled a putative GHRP receptor with an apparent relative molecular mass of 57,000.

    In plain wordsIn lab tests on pituitary membranes, a hexarelin-based probe bound a protein that may be a growth hormone-releasing peptide receptor.

    Peptide
    Hexarelin
    Outcome
    Not applicableGHRP receptor labelling in pituitary membranes
    Study

    human, bovine and porcinen: not reported in source

    anterior pituitary membranes
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones

    Source sentences

    Summary
    A putative GHRP receptor with an apparent relative molecular mass of 57,000 was specifically labelled and characterized in human, bovine and porcine anterior pituitary membranes using this hexarelin derivative.
    1 context sentence
    Summary · context
    In order to confirm such a hypothesis, a photoactivatable derivative of hexarelin, Tyr-p-benzoyl phenylalanine-Ala-hexarelin, was developed.

    In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.

  2. 02LabNot a test of Hexarelin aloneEx vivo tissueMechanism

    Using the same hexarelin derivative, the existence of myocardial GHRP binding sites was demonstrated.

    In plain wordsIn lab tests, the same hexarelin-based probe also found binding sites in heart tissue.

    Peptide
    Hexarelin
    Outcome
    Not applicableMyocardial GHRP binding sites
    Study

    n: not reported in source

    myocardial tissue
    Outcome group
    Receptor activity and mechanism · Cardiovascular

    Source sentences

    Summary
    The existence of myocardial binding sites was also demonstrated using the same approach.
    1 context sentence
    Summary · context
    In order to confirm such a hypothesis, a photoactivatable derivative of hexarelin, Tyr-p-benzoyl phenylalanine-Ala-hexarelin, was developed.

    In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.